JP2023514333A5 - - Google Patents
Info
- Publication number
- JP2023514333A5 JP2023514333A5 JP2022549496A JP2022549496A JP2023514333A5 JP 2023514333 A5 JP2023514333 A5 JP 2023514333A5 JP 2022549496 A JP2022549496 A JP 2022549496A JP 2022549496 A JP2022549496 A JP 2022549496A JP 2023514333 A5 JP2023514333 A5 JP 2023514333A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- administered
- gbq
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207474A JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977932P | 2020-02-18 | 2020-02-18 | |
| US62/977,932 | 2020-02-18 | ||
| PCT/US2021/018447 WO2021168028A1 (en) | 2020-02-18 | 2021-02-18 | Method of treating psma-expressing cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207474A Division JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514333A JP2023514333A (ja) | 2023-04-05 |
| JP2023514333A5 true JP2023514333A5 (https=) | 2024-02-26 |
Family
ID=77391664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549496A Pending JP2023514333A (ja) | 2020-02-18 | 2021-02-18 | Ｐｓｍａ発現がんを処置する方法 |
| JP2025207474A Pending JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207474A Pending JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230098279A1 (https=) |
| EP (1) | EP4107279A4 (https=) |
| JP (2) | JP2023514333A (https=) |
| CN (1) | CN115380117A (https=) |
| WO (1) | WO2021168028A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3533473A3 (en) | 2013-11-14 | 2019-12-18 | Endocyte, Inc. | Compounds for positron emission tomography |
| CN112368024A (zh) | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN118852043A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3456700A1 (en) * | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20150110814A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| MX2019012017A (es) * | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| CN111655288A (zh) * | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| US20200297877A1 (en) * | 2017-12-13 | 2020-09-24 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| CN112368024A (zh) * | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| IL279354B1 (en) * | 2018-06-21 | 2026-02-01 | Regeneron Pharma | Bispecific antibodies against psma and against cd28 and their uses |
-
2021
- 2021-02-18 EP EP21757774.1A patent/EP4107279A4/en active Pending
- 2021-02-18 JP JP2022549496A patent/JP2023514333A/ja active Pending
- 2021-02-18 WO PCT/US2021/018447 patent/WO2021168028A1/en not_active Ceased
- 2021-02-18 US US17/904,442 patent/US20230098279A1/en active Pending
- 2021-02-18 CN CN202180029214.XA patent/CN115380117A/zh active Pending
-
2025
- 2025-11-28 JP JP2025207474A patent/JP2026049728A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514333A5 (https=) | ||
| Li et al. | SPECT/CT imaging of the novel HER2-targeted peptide probe 99mTc-HYNIC-H6F in breast cancer mouse models | |
| Cwikla et al. | Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study | |
| Bander et al. | Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen | |
| Dumont et al. | Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin | |
| van Essen et al. | Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin | |
| Corpetti et al. | Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes | |
| Müller et al. | Prospects in folate receptor-targeted radionuclide therapy | |
| JP2024178159A5 (https=) | ||
| Liu et al. | 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma | |
| RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
| JP2022501441A5 (https=) | ||
| Wang et al. | PSMA-targeted therapy for non-prostate cancers | |
| Liu et al. | Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors | |
| Yoshii et al. | Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts | |
| Sabet et al. | Advances in peptide receptor radionuclide therapy | |
| Lee et al. | Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). | |
| Davisson et al. | Predictors of survival after yttrium-90 radioembolization of chemotherapy-refractory hepatic metastases from breast cancer | |
| Sachindra et al. | SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-integrin αvβ6 cystine knot peptide in a pancreatic cancer xenograft model | |
| Bilgin et al. | Current and future directions in theranostics for neuroendocrine prostate cancer | |
| Sobral et al. | Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy | |
| Holzleitner et al. | Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy | |
| Liu et al. | Exploring the impact of PEGylation on pharmacokinetics: a size-dependent effect of polyethylene glycol on prostate-specific membrane antigen inhibitors | |
| Kroloff et al. | Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report | |
| Zhang et al. | Preclinical evaluation of [211At] At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma |